As of early 2026, Retatrutide (LY3437943) is widely viewed as the most advanced next-generation GLP-1 weight loss drug in development. Following the December 2025 Phase 3 breakthrough—showing 28.7% average weight loss—Eli Lilly has moved into the final regulatory phase.
With results now exceeding those of Wegovy and Zepbound, many patients are asking the same question: Is Retatrutide the best GLP-1 for weight loss?
Table of Contents
- When Will Retatrutide Be Available?
- 2026: Final Phase 3 Results & NDA Submission
- 2027: FDA Review & Approval Outlook
- 2028: Market Launch & Access
- TRIUMPH Phase 3 Results Overview
- Can You Access Retatrutide Before Approval?
- Retatrutide vs Other GLP-1 Drugs (FAQ)
When Will Retatrutide Be Available?
Despite record-setting results, Retatrutide is not FDA approved and cannot be legally prescribed outside of clinical trials. Based on current Phase 3 timelines and FDA review standards, the most realistic availability window is outlined below.
2026: The Year of Final Results
2026 is the most important year for determining whether Retatrutide becomes the best GLP-1 weight loss drug on the market.
- January–May 2026: Final primary completion dates for key TRIUMPH trials, including obesity-only and diabetes populations
- Late 2026: Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA
This submission will include full safety data, cardiometabolic outcomes, and long-term weight maintenance results.
2027: FDA Review — Approval vs Delay
Once submitted, Retatrutide will enter the FDA review phase. This is where it will be directly evaluated against existing GLP-1 drugs like Wegovy and Zepbound.
- Early 2027: Potential for Priority Review, reducing review time from 10 months to ~6 months
- Mid-2027: Earliest possible FDA approval decision, assuming no major safety concerns
If approved on this timeline, Retatrutide would become the highest-efficacy GLP-1 drug ever approved.
2028: Market Launch, Cost & Widespread Access
Even after approval, access may not be immediate for all patients. Like Wegovy and Zepbound, supply constraints are expected initially.
- Early 2028: Expected U.S. commercial launch
- 2028 onward: Manufacturing scale-up and global expansion
Retatrutide cost has not yet been announced, but pricing is expected to align with or exceed existing premium GLP-1 therapies.
TRIUMPH Phase 3 Results: Why Retatrutide Is Different
The TRIUMPH program includes over 5,800 participants and evaluates Retatrutide across multiple obesity-related conditions.
| Trial | Focus | Key Result |
|---|---|---|
| TRIUMPH-1 | General Obesity | Completion expected May 2026 |
| TRIUMPH-2 | Obesity + Type 2 Diabetes | Completion expected 2026 |
| TRIUMPH-3 | Obesity + Cardiovascular Disease | Completion expected May 2026 |
| TRIUMPH-4 | Obesity + Knee Osteoarthritis | 28.7% average weight loss |
| TRIUMPH-8 | Weight Maintenance | Estimated July 2027 |
Can You Get Retatrutide Before FDA Approval?
The only legal way to access Retatrutide before approval is by enrolling in an authorized clinical trial.
Typical Eligibility Requirements
- BMI ≥ 30 (or ≥ 27 with a weight-related condition)
- Age 18+
- History of unsuccessful diet-based weight loss
- No recent use of GLP-1 medications
Common Disqualifiers
- History of pancreatitis
- Bariatric surgery (past or planned)
- Family history of medullary thyroid carcinoma
FAQ: Retatrutide vs Other GLP-1 Drugs
Is Retatrutide legal right now?
Yes—but only within FDA-approved clinical trials. Selling or compounding Retatrutide is illegal until approval.
Is Retatrutide better than Zepbound?
Zepbound (tirzepatide) targets two hormones (GLP-1 and GIP). Retatrutide targets three (GLP-1, GIP, and glucagon), which is believed to explain the superior 28.7% weight loss results.
Pill or injection?
All Phase 3 studies use a once-weekly injectable formulation.
Want to Start Weight Loss Now?
While Retatrutide remains in trials, FDA-approved options like Zepbound and Wegovy are currently available and may be suitable alternatives.